It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.

A positive earnings picture continues to emerge from the fourth-quarter earnings season with both earnings and revenue growth improving compared to recent quarters.

2016 has not been a great year for biotech stocks, which were under intense pressure with issues like increasing political and media focus on high price tags for drugs, and the changing competitive scenario weighing on the sector.

This particular bureaucracy neither gives nor takes. Data do. If a drug works, the company that develops it will do well. If a drug doesn’t work, the company that develops it had better have a diversified pipeline.

Stocks run higher as traders await the Fed’s decision on interest rates. A solid move today by stocks led by the Nasdaq as traders rush into technology stocks.